The round was co-led by seed investors Lansdowne Investment Company Cyprus and IST Cube with participation from newly joined HCVC and tecnet equity. Besides returning seed investors Axilium Holding, Novacapital, and Nina Capital we are particularly happy to welcome newly joined European family offices with industrial biopharmaceutical backgrounds. The financing will fuel the development of Sarcura’s first system prototype.
„We are delighted to have successfully closed this funding round. It reflects the unmet need for breakthrough technologies to address the existing challenges in the manufacturing of cell therapies“ says Daniela Buchmayr, Co-founder and CEO of Sarcura.
Engineered cell therapies bring hope to patients who lack alternatives. With more than 1400 CAR-T clinical trials ongoing, the advanced cell therapy industry has seen unprecedented growth, but the manufacturing of these lifesaving treatments remains a major bottleneck.
„Scientists aim to identify and engineer the right cells, enhancing control while lowering manufacturing cost. Sarcura unites cutting-edge silicon technologies such as integrated photonics in microfluidic cartridges, to automate, miniaturize and bring real-time control to cell therapy manufacturing“ says Daniela Buchmayr.